Study on QOL improvement with the glucide diet which enhanced protein and EPA in advanced colorectal cancer and breast cancer for stage IV

Study on QOL improvement with the glucide diet which enhanced protein and EPA in advanced colorectal cancer and breast cancer for stage IV - Study of the glucide diet for the advanced cancer

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029527

Enrollment

Registered

2017-10-15

Start date

2015-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colorectal cancer, breast cancer

Interventions

An intervention period: The glucide diet is three months by every meal. A daily glucide intake: Less than 5% of intake energy. Daily EPA(eicosapentaenoic acid) intake: More than 2 g. A daily protei

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Advanced colorectal cancer and breast cancer patient of stage IV when standard treatment was not effective. The combination of chemotherapy and the radiation therapy is possible. 1.Cancer with the insurance adaptation of the PET-CT examination. 2.Performance status is 2 from 0. 3.The function of organs is normal, and there is not impaired glucose tolerance. 4.In past three months, a weight loss is less than 5%. 5.BMI(Body mass index) is more than 18 kg/m2.

Exclusion criteria

Exclusion criteria: Diabetic patient Cachexy patient

Design outcomes

Primary

Measure	Time frame
The evaluation is every month after a glucide diet start. Blood sugar level, blood ketone body density, the weight, albumin level, renal function (BUN, Cr), liver function (GOT, GPT), QOL score)	—

Secondary

Measure	Time frame
The evaluation is three month after a glucide diet start. The RECIST evaluation by the examination for CT. Change of the tumor marker	—

Countries

Japan

Contacts

Public ContactKenji Furukawa

Tama-Nanbu regional Hospital Department of Surgery

kenji_furukawa@tokyo-hmt.jp042-338-5111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026